{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T15:53:10Z","timestamp":1773762790507,"version":"3.50.1"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["MCKINZ24Y3-LAD"],"award-info":[{"award-number":["MCKINZ24Y3-LAD"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.atsjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Elexacaftor\/tezacaftor\/ivacaftor (ETI) has been associated with varied effects on mental health (MH) in people with cystic fibrosis (PwCF). Currently published literature has focused primarily on MH diagnoses\/symptoms with ETI as opposed to associated pharmacotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>We sought to evaluate the effect of ETI on MH diagnosis and associated pharmacotherapy in both adult and pediatric PwCF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a multicenter retrospective study in PwCF who started ETI at 7 accredited cystic fibrosis centers. Primary outcomes were the rate of MH diagnosis and medication use pre- and post-ETI initiation. Secondary outcomes were the rate of MH medication changes and dose adjustments pre- and post-ETI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements and Main Results<\/jats:title>\n                    <jats:p>Overall, 1046 PwCF were included, with 453 in the \u201cMH group\u201d because they had either an MH diagnosis and\/or MH medication use at any time point post-ETI. Mental health medication use and diagnosis both significantly increased from baseline at all time points post-ETI initiation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The rate of MH medication use increased significantly from baseline at all time points in PwCF not previously prescribed MH medications, while rate of MH medication use remained consistent for those already on medications pre-ETI.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1513\/annalsats.202505-552oc","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T20:31:42Z","timestamp":1761683502000},"page":"390-396","update-policy":"https:\/\/doi.org\/10.1164\/crossmarkpolicies","source":"Crossref","is-referenced-by-count":0,"title":["Mental health diagnosis and medication changes after initiation of elexacaftor\/tezacaftor\/ivacaftor"],"prefix":"10.1093","volume":"23","author":[{"given":"Cameron J","family":"McKinzie","sequence":"first","affiliation":[{"name":"Department of Pharmacy, University of North Carolina Hospital , Chapel Hill, NC,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Casey R","family":"Tak","sequence":"additional","affiliation":[{"name":"University of Utah College of Pharmacy , Salt Lake City, UT,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0861-0124","authenticated-orcid":false,"given":"Stephanie","family":"Duehlmeyer","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Children\u2019s Mercy Kansas City , Kansas City, MO,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Foushee","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Louisville Hospital , Louisville, KY,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzan","family":"Hua","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of California Davis Health , Sacramento, CA,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morgan C","family":"Jones","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of North Carolina Hospital , Chapel Hill, NC,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca S","family":"Pettit","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Riley Hospital for Children at IU Health , Indianapolis, IN,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of California Davis Health , Sacramento, CA,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma M","family":"Tillman","sequence":"additional","affiliation":[{"name":"Indiana University School of Medicine , Indianapolis, IN,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brittany A","family":"Wright","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Care, University of Iowa Health Care, University of Iowa Health Care , Iowa City, IA,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charissa W","family":"Kam","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of North Carolina Hospital , Chapel Hill, NC,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,10,28]]},"reference":[{"key":"2026031709570119200_aaoaf034-B1","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"2026031709570119200_aaoaf034-B2","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomized, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"2026031709570119200_aaoaf034-B3","volume-title":"Elexacaftor\/Tezacaftor\/Ivacaftor [Package Insert]","author":"Kaftrio","year":"2024"},{"key":"2026031709570119200_aaoaf034-B4","volume-title":"Elexacaftor\/Tezacaftor\/Ivacaftor) [Package Insert]","author":"Trikafta","year":"2024"},{"key":"2026031709570119200_aaoaf034-B5","doi-asserted-by":"publisher","first-page":"e70007","DOI":"10.1111\/crj.70007","article-title":"Analysis of depression and anxiety scores following initiation of elexacaftor\/tezacaftor\/ivacaftor in adults with cystic fibrosis","volume":"18","author":"Pudukodu","year":"2024","journal-title":"Clin Respir J"},{"key":"2026031709570119200_aaoaf034-B6","doi-asserted-by":"publisher","first-page":"e27393","DOI":"10.1002\/ppul.27393","article-title":"Mental health of pediatric patients with cystic fibrosis after 18 months on elexacaftor-tezacaftor-ivacaftor therapy","volume":"60","author":"Pasley","year":"2025","journal-title":"Pediatr Pulmonol"},{"key":"2026031709570119200_aaoaf034-B7","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1164\/rccm.202308-1525OC","article-title":"Elexacaftor\/tezacaftor\/ivacaftor treatment and depression-related events","volume":"209","author":"Ramsey","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"2026031709570119200_aaoaf034-B8","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1002\/ppul.26412","article-title":"Management of neuropsychiatric symptoms in adults treated with elexacaftor\/tezacaftor\/ivacaftor","volume":"58","author":"Baroud","year":"2023","journal-title":"Pediatr Pulmonol"},{"key":"2026031709570119200_aaoaf034-B9","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.chest.2023.10.043","article-title":"Longitudinal effects of elexacaftor\/tezacaftor\/ivacaftor: multidimensional assessment of neuropsychological side effects and physical and mental health outcomes in adolescents and adults","volume":"165","author":"Graziano","year":"2024","journal-title":"Chest"},{"key":"2026031709570119200_aaoaf034-B10","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1002\/ppul.27100","article-title":"Mental health, sleep, and respiratory health after initiating elexacaftor\/tezacaftor\/ivacaftor treatment in children with cystic fibrosis","volume":"59","author":"Pham","year":"2024","journal-title":"Pediatr Pulmonol"},{"key":"2026031709570119200_aaoaf034-B11","doi-asserted-by":"publisher","first-page":"23cr03649","DOI":"10.4088\/PCC.23cr03649","article-title":"A case of elexacaftor\/tezacaftor\/ivacaftor-induced depressive symptoms and suicidal thoughts","volume":"26","author":"Godier","year":"2024","journal-title":"Prim Care Companion CNS Disord"},{"key":"2026031709570119200_aaoaf034-B12","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.jcf.2023.01.015","article-title":"Suicide attempts in adolescents with cystic fibrosis on elexacaftor\/tezacaftor\/ivacaftor therapy","volume":"22","author":"Arslan","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2026031709570119200_aaoaf034-B13","doi-asserted-by":"publisher","first-page":"3734","DOI":"10.1002\/ppul.27242","article-title":"Severe mental health changes in patients with cystic fibrosis on elexacaftor\/tezacaftor\/ivacaftor therapy","volume":"59","author":"McKinzie","year":"2024","journal-title":"Pediatr Pulmonol"},{"key":"2026031709570119200_aaoaf034-B14","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jcf.2024.09.020","article-title":"Suicidal behavior and CFTR modulators: a case series and WHO database disproportionality analysis","volume":"24","author":"Nidegger","year":"2025","journal-title":"J Cyst Fibros"},{"key":"2026031709570119200_aaoaf034-B15","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1002\/ppul.26527","article-title":"Positive and negative impacts of elexacaftor\/tezacaftor\/ivacaftor: healthcare providers\u2019 observation across US centers","volume":"58","author":"Bathgate","year":"2023","journal-title":"Pediatr Pulmonol"},{"key":"2026031709570119200_aaoaf034-B16","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jcf.2024.07.008","article-title":"Assessing the impact of elexacaftor\/tezacaftor\/ivacaftor on anxiety & depression symptom scores in adults with cystic fibrosis","volume":"24","author":"Nguyen","year":"2025","journal-title":"J Cyst Fibros"},{"key":"2026031709570119200_aaoaf034-B17","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1097\/MCP.0000000000001014","article-title":"Neuropsychiatric adverse effects from CFTR modulators deserve a serious research effort","volume":"29","author":"VanElzakker","year":"2023","journal-title":"Curr Opin Pulm Med"},{"key":"2026031709570119200_aaoaf034-B18","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1164\/rccm.202311-2159ED","article-title":"Questions and answers? Depression symptoms associated with elexacaftor\/tezacaftor\/ivacaftor treatment for cystic fibrosis","volume":"209","author":"Lee","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"2026031709570119200_aaoaf034-B19","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.jcf.2024.11.006","article-title":"Elexacaftor\/tezacaftor\/ivacaftor and mental health: a workshop report from the cystic fibrosis foundation\u2019s prioritizing research in mental health working group","volume":"24","author":"Bathgate","year":"2025","journal-title":"J Cyst Fibros"},{"key":"2026031709570119200_aaoaf034-B20","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/S0140-6736(21)02143-7","article-title":"Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories due to the COVID-19 pandemic","volume":"398","author":"COVID-19 Mental Disorders Collaborators","year":"2021","journal-title":"Lancet"},{"key":"2026031709570119200_aaoaf034-B21","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1136\/thoraxjnl-2014-205983","article-title":"Prevalence of depression and anxiety in patients with cystic fibrosis and parent caregivers: results of the international depression epidemiological study across nine countries","volume":"69","author":"Quittner","year":"2014","journal-title":"Am J Resp Crit Care Med"}],"container-title":["Annals of the American Thoracic Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/annalsats\/advance-article-pdf\/doi\/10.1513\/AnnalsATS.202505-552OC\/66545266\/annalsats.202505-552oc.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/23\/3\/390\/66545266\/annalsats.202505-552oc.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/23\/3\/390\/66545266\/annalsats.202505-552oc.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T13:57:06Z","timestamp":1773755826000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/annalsats\/article\/23\/3\/390\/8438741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,28]]},"references-count":21,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,10,28]]},"published-print":{"date-parts":[[2026,3,1]]}},"URL":"https:\/\/doi.org\/10.1513\/annalsats.202505-552oc","relation":{},"ISSN":["2329-6933","2325-6621"],"issn-type":[{"value":"2329-6933","type":"print"},{"value":"2325-6621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2025,10,28]]},"assertion":[{"value":"2025-05-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}